← 返回

细胞因子筛选发现 TNF 可能增强儿童肉瘤的免疫原性

英文原题:Cytokine screening identifies TNF to potentially enhance immunogenicity of pediatric sarcomas.

查看英文原题

Cytokine screening identifies TNF to potentially enhance immunogenicity of pediatric sarcomas.

PubMed 2024/12/11(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们的研究支持使用 TNF 或诱导 TNF 的方案上调儿童肉瘤细胞上的 MHC-I 和共刺激表面分子,并增强抗原特异性 CD8 + T 细胞对具有反应性的 HLA-A2 + EwS 肿瘤细胞的识别。

研究思路结论见上方概要

儿童肉瘤,包括骨肉瘤(OS)、尤文肉瘤(EwS)和横纹肌肉瘤(RMS),具有低体细胞突变负荷和低MHC-I表达,对T细胞疗法构成挑战。我们先前的研究表明,单核细胞成熟介质使EwS细胞系A673对HLA-A*02:01/CHM1 319特异性同种限制性T细胞受体(TCR)转基因CD8+ T细胞(CHM1 319 CD8+ T细胞)的裂解敏感。

在本研究中,我们使用流式细胞术检测了一组单核细胞成熟细胞因子上调OS、EwS和RMS细胞系上免疫原性细胞表面标志物的能力。使用xCELLigence、SRB和ELISpot试验评估TNF预处理是否增加CD8+ T细胞细胞毒性。

我们观察到TNF和IL-1β上调了儿童肉瘤细胞系表面的MHC I类分子、ICAM-1以及CD83和PD-L1,而IL-4、GM-CSF、IL-6和PGE 2未能诱导相应效应。尽管用TNF预处理儿童肉瘤细胞系并未提高非特异性外周血单核细胞(PBMCs)的细胞毒性,但TNF依赖MHC-I表达和ICAM-1上调,增强了CHM1 319 CD8 + T细胞对1/3 HLA-A2 + EwS细胞系的特异性裂解。

展开英文摘要原文

In this study, we tested a panel of monocyte maturation cytokines for their ability to upregulate immunogenic cell surface markers on OS, EwS and RMS cell lines, using flow cytometry. xCELLigence, SRB and ELISpot assays were used to assess whether TNF pretreatment increases CD8 + T cell cytotoxicity.

We observed that TNF and IL-1β upregulated MHC class I, ICAM-1 as well as CD83 and PD-L1 on the surface of pediatric sarcoma cell lines, while IL-4, GM-CSF, IL-6 and PGE 2 failed to induce respective effects. Although pretreatment of pediatric sarcoma cell lines with TNF did not improve unspecific peripheral blood mononuclear cells (PBMCs) cytotoxicity, TNF enhanced specific lysis of 1/3 HLA-A2 + EwS cell lines by CHM1 319 CD8 + T cells depending on MHC-I expression and ICAM-1 upregulation. DISCUSSION: Our study supports utilization of TNF or TNF-inducing regimens for upregulation of MHC-I and costimulatory surface molecules on pediatric sarcoma cells and for enhancing recognition of responsive HLA-A2 + EwS tumor cells by antigen-specific CD8 + T cells.

论文信息

作者
Gassmann H、Thiede M、Weiß J、Biele E、Flohé L、Lachermaier H、Prexler C、Evdokimova V
单位
Department of Pediatrics, Children's Cancer Research Center, Kinderklinik München Schwabing, TUM School of Medicine, Technical University of Munich, Munich, Germany.Germany
文献类型
非美国政府资助研究 · 美国 NIH 资助研究
期刊
Frontiers in immunology2024
原文标识
PubMed 39723214 · DOI 10.3389/fimmu.2024.1347404